Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2019 May 21;8(10):e012524.
doi: 10.1161/JAHA.119.012524.

Is There a Real Association Between Paclitaxel Devices and Mortality? Time to Pause and Re-Evaluate What We Know About This Statistical Finding

Mehdi H Shishehbor  1 , Eric A Secemsky  2   3 , Ramon L Varcoe  4   5
Affiliations
Comment

Is There a Real Association Between Paclitaxel Devices and Mortality? Time to Pause and Re-Evaluate What We Know About This Statistical Finding

Mehdi H Shishehbor et al. J Am Heart Assoc. .
No abstract available

Keywords: drug delivery; drug‐eluting balloon; drug‐eluting stent; mortality rate; peripheral artery disease.

PubMed Disclaimer

Comment on

References

    1. Shishehbor MH, Jaff MR, Beckman JA, Misra S, Schneider PA, Lookstein R, Kashyap VS, Aronow HD, Jones WS, White CJ. Public health impact of the Centers for Medicare and Medicaid Services decision on pass‐through add‐on payments for drug‐coated balloons: a call to action. JACC Cardiovasc Interv. 2018;11:496–499. - PubMed
    1. Shishehbor MH, White CJ, Beckman JA, Misra S, Schneider PA, Lookstein RA, Kashyap VS, Clair D, Jones WS, Rosenfield K, Katzen BT, Jaff MR. Centers for Medicare & Medicaid Services’ decision on drug‐coated balloons: no additional reimbursement despite higher cost and highest levels of scientific evidence. Vasc Med. 2018;23:558–559. - PubMed
    1. Dake MD, Ansel GM, Jaff MR, Ohki T, Saxon RR, Smouse HB, Machan LS, Snyder SA, O'Leary EE, Ragheb AO, Zeller T; Zilver PTXI . Durable clinical effectiveness with paclitaxel‐eluting stents in the femoropopliteal artery: 5‐year results of the Zilver PTX randomized trial. Circulation. 2016;133:1472–1483; discussion 1483. - PMC - PubMed
    1. Tepe G, Schnorr B, Albrecht T, Brechtel K, Claussen CD, Scheller B, Speck U, Zeller T. Angioplasty of femoral‐popliteal arteries with drug‐coated balloons: 5‐year follow‐up of the THUNDER trial. JACC Cardiovasc Interv. 2015;8:102–108. - PubMed
    1. Salisbury AC, Li H, Vilain KR, Jaff MR, Schneider PA, Laird JR, Cohen DJ. Cost‐effectiveness of endovascular femoropopliteal intervention using drug‐coated balloons versus standard percutaneous transluminal angioplasty: results from the IN.PACT SFA II Trial. JACC Cardiovasc Interv. 2016;9:2343–2352. - PubMed

LinkOut - more resources